USPTO serial 86881253
COSIMIA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- GAYNOR, BARBARA ANNE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with COSIMIA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Brent A. Harris
Brent A. Harris Roche Diagnostics Operations, Inc.9115 Hague RoadIndianapolis, IN 46250UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | In vitro diagnostic agents, namely, chemical control solutions for calibrating and monitoring the accuracy and function of instruments and test results, chemical additives, enzymes, reagents, organisms and proteins for use in science, research and industry; reagents for cell separation for scientific or research purposes; labeling reagents for scientific or research purposes; reagents for the processing, separation, isolation, enrichment, depletion, detection, screening, cultivation, analysis and counting of material, in particular of chemicals and biological material, all for scientific or research purposes; reagents featuring magnetic beads for scientific or research purposes; antibody reagents for scientific or research purposes; buffer solutions and reagents for use with laboratory apparatus, namely, separation apparatus and analysis apparatus, for scientific or research purposes; reagents for processing biological material, namely, tissue, bone marrow, cells, blood and components thereof for scientific or research purposes; reagents, enzymes, and nucleotides for nucleic acid sequencing for scientific or research purposes; diagnostic tests comprised of reagents and chemical test kits for determination of genetic information for scientific or research purposes; reagents for scientific or medical research use for analyzing cells, proteins, nucleic acids, sequencing DNA, genotyping, gene expression profiling and high through-put screening; reagent kits composed primarily of oligonucleotides, enzymes and buffers for nucleic acid detection in the fields of scientific, pharmaceutical and medical research; nucleic acids, enzymes, buffers and chemical reagents for use in genotyping and gene expression test kits for detecting and analyzing nucleic acids for scientific or research purposes; assays and reagents for scientific or medical research use; diagnostic tests and test kits primarily composed of reagents and nucleotides for determination of genetic information for scientific or research purposes; reagents and chemical test kits for scientific and research use in connection with DNA sequencing and genetic analysis | ACTIVE | — |
| 005 | In vitro diagnostic agents, namely, reagents and control solutions for analysis of biological samples, all for medical diagnostic purposes; reagents for medical diagnostic use; medical diagnostic assays and reagents for testing of biological samples; reagent kits consisting of enzymes, oligonucleotides, nucleic acids, natural and modified nucleotides, buffers, labels, and substrates for medical diagnostic purposes; medical diagnostic test kits comprising reagents for testing body fluids to determine fetal chromosomal abnormalities; chemical reagents, preparations and test kits for fetal nucleic acid analysis for medical use; diagnostic kits consisting primarily of reagents for nucleic acid detection and analysis for medical diagnostic purposes; reagents for medical diagnostic use and diagnostic kits comprised of medical diagnostic reagents and assays for use in connection with DNA sequencing and genetic analysis | ACTIVE | — |
| 009 | Scientific equipment, apparatus and instruments, namely, genome sequencer for scientific, pharmaceutical and medical research purposes; scientific instruments for use in scientific research, namely, nucleic acid sequencers, imaging devices and analyzers; laboratory apparatus for sample preparation, amplification, mixing, hybridization, incubation, and washing, namely, arrays, beads, bead sets and flow cells; laboratory equipment, namely, devices for analysis of nucleic acids and for DNA sequencing; automated laboratory apparatus and systems, namely, sample loaders and bar code readers; software used for genotyping and gene expression microarrays for scientific, pharmaceutical and medical research purposes; software used in analyzing, managing and visualizing DNA sequencing data; software used for preparation of nucleic acids libraries; computer hardware and software for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, for use in the fields of scientific, diagnostic and clinical research and for clinical diagnostic purposes | ACTIVE | — |
| 010 | Clinical or medical diagnostic apparatus and instruments, namely, nucleic acid sequencers, imaging devices and analyzers; medical diagnostic apparatus and instruments for the amplification and analysis of nucleic acids and the preparation of nucleic acid libraries sold together in the form of kit; medical equipment, namely, devices for analyzing nucleic acids and for DNA sequencing for the purpose of rendering medical treatment and diagnosis, and software for use therewith sold as a unit | ACTIVE | — |
| 042 | Scientific research in the field of genome sequence analysis and reporting; medical research in the field of genome sequence analysis and reporting; DNA screening for scientific research purposes; providing reagent sample testing services for others in the fields of science and scientific research; computer services, namely, cloud hosting provider services for storing, analyzing and sharing biological information; computer services, namely, hosting an interactive web site that allows users to store, analyze and share data in the field of life science; technical support services, namely, infrastructure management services for monitoring, administration and management of cloud computing IT and application systems in the field of life science; consulting services in the field of cloud computing in the field of life science; providing online non-downloadable software for the custom design and ordering of assays and reagents; design and development of laboratory apparatus, instruments and computer systems for use in analysis of biomolecules; installation and maintenance of computer software and database systems used in the field of analysis of biomolecules; consultancy, information and advisory services in the field of scientific analysis of biomolecules; product development, namely, developing equipment for use in preparing, detecting, analyzing and sequencing nucleic acids and other biological molecules, and automated laboratory equipment and systems, and computer systems for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data to the order and specification of others, all the foregoing in the fields of scientific and clinical research; clinical diagnostic services in preparing, amplifying, labeling, detecting, analyzing and sequencing nucleic acids and other biological molecules from human beings or animals for scientific and medical research purposes; design and development of medical diagnostic apparatus and instruments and computer systems for use in analysis of biomolecules; scientific consulting and research services and clinical laboratory testing services in the fields of amplification, detection, sequencing and analysis of nucleic acids and the preparation of nucleic acid libraries; nucleic acid sequencing services for scientific research purposes; scientific research, namely, computational analysis of nucleic acid sequences and development of computational technologies for the analysis of nucleic acid sequences | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Roche Molecular Systems, Inc.
- Other trademarks owned by Roche Molecular Systems, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named COSIMIA
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 28, 2019 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 28, 2019 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 2, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 2, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 2, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 1, 2019 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Apr 1, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Mar 27, 2019 | EXT5 | SOU EXTENSION 5 FILED | — |
| Mar 27, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 9, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 9, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 29, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Sep 27, 2018 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Sep 27, 2018 | EXT4 | SOU EXTENSION 4 FILED | — |
| Sep 27, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 24, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Feb 22, 2018 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Feb 22, 2018 | EXT3 | SOU EXTENSION 3 FILED | — |
| Feb 22, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 9, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Sep 7, 2017 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 7, 2017 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 7, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 28, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Mar 24, 2017 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 24, 2017 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 24, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 27, 2016 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 2, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 13, 2016 | NPUB | NOTICE OF PUBLICATION | — |
| Jun 29, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 28, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 27, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 27, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 10, 2016 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 9, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 4, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 26, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 23, 2016 | NWAP | NEW APPLICATION ENTERED | — |